On Air Now

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 1360 AM Northeast, WI 97.5 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
60° Feels Like: 60°
Wind: ESE 5 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Partly Cloudy 60°

Tomorrow

Thunderstorms 74°

Fri Night

Heavy Thunderstorms 64°

Alerts

Gilead, Teva reach settlement in Viread patent lawsuit

A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011. REUTERS/
A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011. REUTERS/

(Reuters) - Gilead Sciences Inc said it has agreed with Israel's Teva Pharmaceuticals Industries Ltd to settle a lawsuit relating to patents protecting Viread, a treatment for HIV infection and chronic hepatitis B.

As per the agreement, Gilead said Teva will be allowed to launch a generic version of Viread on December 15, 2017.

"This settlement removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation," Gilead's chief operating officer, John Milligan, said in a statement late on Tuesday.

Gilead, based in California, is the world's largest maker of branded drugs to treat the human immunodeficiency virus, the cause of AIDS.

The trial in the lawsuit, which was scheduled to begin on February 20 in a Manhattan court, has been adjourned to finalize the settlement, Gilead said.

(Reporting by Sakthi Prasad in Bangalore; Editing by Matt Driskill)

Comments